Sanofi expands Regeneron immunology alliance in deal valued at up to $8 billion
Sanofi will pay Regeneron $1 billion upfront and up to $7 billion in milestones to develop four long-acting immunology antibodies, while settling prior litigation.
Financial structure of the expanded alliance
French pharmaceutical company Sanofi agreed on 1 October 2026 to expand its immunology alliance with US partner Regeneron Pharmaceuticals in a transaction valued at up to $8 billion. Under the terms of the revised agreement, Sanofi will make an immediate upfront payment of $1 billion to Regeneron. The contract specifies potential milestone payments of up to $7 billion, which depend on achieving clinical, regulatory, and commercial targets across four newly added drug programs. The investment secures Sanofi access to four experimental antibody candidates discovered by Regeneron. The two drugmakers will share all ongoing development costs and future commercial earnings on an equal fifty-fifty basis.
- Upfront payment
- 1 $B
- Maximum milestone payments
- 7 $B
Division of development and commercial roles
The expanded collaboration agreement covers four next-generation, long-acting antibody therapies designed to treat immune system disorders. Regeneron, which discovered all four molecules, will direct research activities and pilot early preclinical development. Sanofi will co-fund clinical trial programs and assume primary leadership over global commercial operations if regulatory authorities approve the treatments for commercial release. The agreement also provides Regeneron with the option to introduce additional treatment candidates into the shared framework at a later date. George D. Yancopoulos, co-chairman of the board of directors, president, and chief scientific officer of Regeneron, outlined the scientific objectives in a joint announcement.
By combining Regeneron's world-class expertise in scientific discovery and antibody development with Sanofi's global capabilities and reach, we hope to once again deliver the next wave of innovation in immunology.
Succession strategy for Dupixent exclusivity
The new research agreement provides a succession pipeline for Dupixent, the monoclonal antibody co-developed by the two companies. Dupixent functions by targeting specific overactive immune reactions and treats inflammatory diseases including atopic eczema and asthma, generating 15.7 billion euros in global revenue. Market exclusivity for Dupixent is scheduled to expire in the early 2030s, creating an approaching patent cliff. The four newly added antibody candidates target the same biological mechanisms as Dupixent while offering extended duration of action. Sanofi is committing capital to these four unmarketed molecules to replenish its long-term immunology portfolio.
- Sanofi and Regeneron establish initial research collaboration
- Companies agree to $8 billion alliance expansion and settle litigation
- Market exclusivity for blockbuster drug Dupixent is scheduled to expire
Legal settlement and historical partnership
The agreement also resolves previous disputes between the two pharmaceutical companies. The partners confirmed that they have formally settled earlier litigation related to their collaboration. Sanofi and Regeneron have maintained a research partnership since 2003, having jointly created multiple antibody treatments over that period. Following the disclosure of the expanded deal, Sanofi shares increased by 1.64%, while Regeneron shares advanced by 1.03% in equity trading.
